Contact Sal Braico at (608)
441-2890 or sbraico@conjugon.com
FOR IMMEDIATE RELEASE
October 4, 2004 Madison, WI – ConjuGonT announces today that it has
successfully raised a $1.1 million investment round from angel
investors. ConjuGon will use this capital to fund the research and
development of novel biotherapeutics to combat antibiotic-resistant
bacterial infections.
“We are thrilled to close this investment round. This capital allows us
to continue and expand our important research.” said ConjuGon CEO
Christopher Price.
ConjuGon has raised nearly $2.8 million in capital to date, including
$1.9 million from angel investors, and $290,000 in economic development
loans from the Madison Development Corporation and the Wisconsin
Department of Commerce. The company has also been awarded $600,000 in
Small Business Innovation Research (SBIR) grants from the National
Science Foundation.
ConjuGon is developing fundamentally new technologies to combat the
growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance
is a medical crisis, globally responsible for hundreds of thousands of
deaths each year. ConjuGon’s core technology is a new way to kill
unwanted and even multi-drug resistant bacteria. The company, which has
an experienced staff of eight, is located in the MG&E Innovation Center
in Madison.
